SPECT/CT, PET/CT, and PET/MRI for Response Assessment of Bone Metastases

Nazanin Zamani-Siahkali; Seyed Ali Mirshahvalad; Abolfazl Farbod; Ghasemali Divband; Christian Pirich; Patrick Veit-Haibach; Gary Cook; Mohsen Beheshti

doi:10.1053/j.semnuclmed.2023.11.005

SPECT/CT, PET/CT, and PET/MRI for Response Assessment of Bone Metastases

Semin Nucl Med. 2024 May;54(3):356-370. doi: 10.1053/j.semnuclmed.2023.11.005. Epub 2024 Jan 3.

Authors

Nazanin Zamani-Siahkali¹, Seyed Ali Mirshahvalad², Abolfazl Farbod¹, Ghasemali Divband³, Christian Pirich⁴, Patrick Veit-Haibach⁵, Gary Cook⁶, Mohsen Beheshti⁷

Affiliations

¹ Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, Austria; Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran.
² Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, Austria; Joint Department of Medical Imaging, University Medical Imaging Toronto, University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, Toronto, Canada.
³ Department of Nuclear Medicine, Jam Hospital, Tehran, Iran.
⁴ Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, Austria.
⁵ Joint Department of Medical Imaging, University Medical Imaging Toronto, University Health Network, Sinai Health System, Women's College Hospital, University of Toronto, Toronto, Canada.
⁶ Cancer Imaging Department, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
⁷ Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital, Paracelsus Medical University, Salzburg, Austria. Electronic address: m.beheshti@salk.at.

PMID: 38172001
DOI: 10.1053/j.semnuclmed.2023.11.005

Abstract

Recent developments in hybrid SPECT/CT systems and the use of cadmium-zinc-telluride (CZT) detectors have improved the diagnostic accuracy of bone scintigraphy. These advancements have paved the way for novel quantitative approaches to accurate and reproducible treatment monitoring of bone metastases. PET/CT imaging using [¹⁸F]F-FDG and [¹⁸F]F-NaF have shown promising clinical utility in bone metastases assessment and monitoring response to therapy and prediction of treatment response in a broad range of malignancies. Additionally, specific tumor-targeting tracers like [^99mTc]Tc-PSMA, [⁶⁸Ga]Ga-PSMA, or [¹¹C]C- or [¹⁸F]F-Choline revealed high diagnostic performance for early assessment and prognostication of bone metastases, particularly in prostate cancer. PET/MRI appears highly accurate imaging modality, but has associated limitations notably, limited availability, more complex logistics and high installation costs. Advances in artificial intelligence (Al) seem to improve the accuracy of imaging modalities and provide an assistant role in the evaluation of treatment response of bone metastases.

Publication types

Review

MeSH terms

Bone Neoplasms* / diagnostic imaging
Bone Neoplasms* / secondary
Humans
Magnetic Resonance Imaging* / methods
Positron Emission Tomography Computed Tomography* / methods
Single Photon Emission Computed Tomography Computed Tomography* / methods
Treatment Outcome